Drug trial led by Cincinnati researchers gains national media attention

Dr. Evan Stein, director of the Metabolic and Atherosclerosis Research Center in Cincinnati, is leading clinical trials for a new drug candidate (REGN727) that may do a better job of lowering cholesterol than statins, and with fewer side effects. The New York Times and ABC News took notice last month.

Dr. Evan Stein

Study results were published in a recent issue of The New England Journal of Medicine.

“About 5 to 10 percent of people can’t tolerate statins at all, and more can’t tolerate higher doses,” said Dr. Evan A. Stein, director of the Metabolic and Atherosclerosis Research Center in Cincinnati and lead author of the drug trials. “It’s still early in development, but for them this is potentially a most promising alternative.”

Recent Posts

Blog Post Archive

Blog Post Categories

Search the Blog

Newsticker


BioOhio Member Mark BioOhio Member

43North competition awards OSU student’s Genetesis $260K and People’s Choice award | Columbus Business First, October 31, 2014

New study shows combining GanedenBC30 with prebiotics provides digestive health benefits | Ganeden, October 30, 2014

Charles River acquires ChanTest for up to $54M | GEN, October 30, 2014

Ashland Specialty Ingredients launches web-based film-coatings troubleshooting tool and new pharmaceutical excipients website | PR Web, October 30, 2014

IBM and Cleveland Clinic use Watson to advance genomic research for cancer care pilot | PR Newswire, October 29, 2014

Cleveland Clinic announces Top Ten medical innovations for 2015, mobile stroke unit and Dengue vaccine top list (video) | Cleveland.com, October 29, 2014

Ampersand Capital Partners exits ChanTest investment with sale to Charles River Laboratories | PR Newswire, October 29, 2014

Camargo Pharmaceutical Services meets growing client needs with appointment of industry leader Steven Castillo as Vice President Of Drug Development | BioSpace, October 29, 2014

Scientific breakthrough at Cincinnati Children’s Hospital Medical Center could help battle cancer, ulcers | Cincinnati Business Courier, October 29, 2014

Devicor Medical Products of Sharonville, Ohio acquired by Danaher Corporation’s Leica Biosystems | Cincinnati.com, October 28, 2014

GTCR announces sale of Devicor Medical Products to Danaher Corporation’s Leica Biosystems | Business Wire, October 28, 2014

Researchers at Cincinnati Children’s Hospital Medical Center studying how to create replacement organs for people who need transplants | Cincinnati Business Courier, October 28, 2014

Juventas Therapeutics strengthens management team with new senior vice president of finance and operations, Troy Ignelzi | PR Newswire, October 28, 2014

Enable Injections signs strategic development agreement with CSL Behring to market novel drug delivery device | Philadelphia Business Journal, October 28, 2014

Ohio’s 2014 Bioproduct World Conference names Magic Dirt of Little Rock, Arkansas the Bioproduct Innovation of the Year | Wisconsin State Farmer, October 28, 2014

Ohio Soybean Council Foundation offers $36,000 in scholarships, majors include biotechnology | Ohio Soybean Council Foundation, October 28, 2014

Danaher’s Leica Biosystems division agrees to buy Devicor Medical Products, a developer of breast biopsy products | MASS Device, October 28, 2014

University Hospitals selects GenomOncology’s GO Clinical Workbench to launch their first NGS-based cancer diagnostic test | PR Newswire, October 27, 2014

INC Research of Raleigh, NC and the former Kendle location in Cincinnati, OH, plans IPO of up to $156M | Triangle Business Journal, October 27, 2014

NASA Glenn Research Center’s new office building is an example of continued commitment to Brook Park | Cleveland.com, October 27, 2014